Plasma cell myeloma
Not recruitingStudy Comparing Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Patients with Untreated Multiple Myeloma Not Planning Stem Cell Transplant
Study Comparing Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Patients with Untreated Multiple Myeloma Not Planning Stem Cell Transplant
- Disease:Plasma cell myeloma
- Substances:BortezomibDaratumumab+3
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Bortezomib
- Sponsor:Janssen Cilag International













